Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Express News | Gilead Sciences Inc - Lenacapavir Shows 96% Reduction in Hiv Infections in Purpose 2 Trial
Express News | Gilead - Gilead to Begin Regulatory Filings for Lenacapavir for Prep by End of 2024
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Express News | Gilead Presents Additional Efficacy, Safety and Demographic Data From Purpose 2 Trial at 5TH Hiv Research for Prevention Conference